Adma Biologics (ADMA) Other Operating Expenses (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Other Operating Expenses data on file, last reported at $1.2 million in Q4 2025.

• Quarterly Other Operating Expenses fell 9.6% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (up 7.53% YoY) and the FY2025 annual result came in at $5.0 million, up 7.49% from the prior year.
• Other Operating Expenses retreated to $1.2 million in Q4 2025, from $1.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $5.3 million in Q4 2022 to a low of $646000.0 in Q3 2023.
• A 5-year average of $2.3 million and a median of $1.4 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2021 — Other Operating Expenses surged 110.58% — and 2023, when it plunged 87.18%.
• Tracing ADMA's Other Operating Expenses over 5 years: stood at $4.3 million in 2021, then climbed by 23.16% to $5.3 million in 2022, then slumped by 83.44% to $872000.0 in 2023, then surged by 49.31% to $1.3 million in 2024, then retreated by 9.6% to $1.2 million in 2025.
• The last three Other Operating Expenses figures came in at $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.